One case of peripheral eosinophilia induced by posaconazole oral suspension

doi:10.19803/j.1672-8629.2022.08.22

Abstract

Abstract: Objective To explore treatments against peripheral eosinophilia induced by posaconazole oral suspension. Methods The process of diagnosing and treating one case of peripheral eosinophilia induced by posaconazole oral suspension was analyzed. The mechanism by which posaconazole oral suspension induced peripheral eosinophilia was studied with reference to literature. Results The patient was diagnosed with peripheral eosinophilia 23 days after he took posaconazole oral suspension, accompanied by head and face swelling, rash and pruritus. The drug was suspended immediately. The patient’s condition gradually improved after the treatment with oral loratadine tablets, intravenous calcium gluconate injection and dexamethasone sodium phosphate injection. Head and face swelling subsided, skin rash was significantly mitigated, and itching disappeared within 10 days of withdrawal. Posaconazole suspension was taken a second time because of the patient’s condition. Dexamethasone sodium phosphate injection was injected intravenously before each oral posaconazole suspension before peripheral eosinophils gradually returned to normal. Conclusion The use of posaconazole suspension should be stopped immediately after the occurrence of peripheral eosinophilia, and dexamethasone can be injected intravenously before medication.

Key words: posaconazole, oral suspension, peripheral eosinophilia, adverse drug reaction

CLC Number:

R994.11
R978

ZHONG Yunming, Li Cheng, Deng Yingming, XIONG Tianzeng, MENG Xiaobin, Lei Nanfeng, LIANG Pei. One case of peripheral eosinophilia induced by posaconazole oral suspension[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 921-923.

References

[1] TORRES HA, HACHEM RY, CHEMALY RF, et al.Posaconazole: a broad-spectrum triazole antifungal[J]. Lancet Infect Dis, 2005, 5(12): 775-785.
[2] TACKE D, KOEHLER P, MARKIEFKA B, et al.Our 2014 approachto mucormycosis[J]. Mycoses, 2014, 57(9): 519-524.
[3] CORNELY OA, ARIKAN-AKDAGLI S, DANNAOUI E, et al.ESCMID and ECMM joint clinical guide-lines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect, 2014, 20(3): 5-26.
[4] RILEY TT, MUZNY CA, SWIATLO E, et al.Breaking the mold: a review of mucormycosis and current pharmacological treatment options[J]. Ann Pharmacother, 2016, 50(9): 747-757.
[5] VAZQUEZ JA, SKIEST DJ, NIETO L, et al.A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS[J]. Clin Infect Dis, 2006, 42(8): 1179-1186.
[6] CORNELY OA, MAERTENS J, WINSTON DJ, et al.Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia[J]. N Engl J Med, 2007, 356(4): 348-359.
[7] ULLMANN AJ, LIPTON JH, VESOLE DH, et al.Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease[J]. N Engl J Med, 2007, 356(4): 335-347.
[8] VISHNUBHOTLA P, IBRAHIM RB, ABIDI MH, et al.Fever and eosinophilia associated with voriconazole[J]. Ann Pharmacother, 2004, 38(5): 900-901.
[9] GRZEGORCZYK B, MURATA Y.Peripheral eosinophilia and eosinophilic colitis during long-term azole therapy for pulmonary aspergillosis[J]. JMM Case Rep, 2014, 1(4): e004135.
[10] MAHER A, RAE-KIRAN J, TERENCE W, et al.Marked peripheral eosinophilia due to prolonged administration of posaconazole[J]. JMM Case Rep, 2017, 4(6): e005100.
[11] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[12] NARANJO, CLAUDIO A, SHEAR, et al. Advances in the diagnosis of adverse drug reactions[J]. Journal of Clinical Pharmacology, 1992, 329(10): 897-904.
[13] LI X, CHU YQ.A case skin rash eosinophilia caused by tigecycline[J]. Clinical Medicaion Journal(临床药物治疗杂志), 2019, 17(11): 90-92.
[14] CUI HX, YU SW.Retrospective analysis of 125 cases of adverse drug reactions induced by tigecycline[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(8): 489-492.
[15] WALSH TJ, ANAISSIE EJ, DENNING DW, et al.Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America[J]. Clin Infect Dis, 2008, 46(3): 327-360.
[16] FREIFELD AG, BOW EJ, SEPKOWITZ KA, et al.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2011, 52(4): 56-93.
[17] STEVENS DL, BISNO AL, CHAMBERS HF, et al.Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2014, 59(2): 10-52.
[18] PERFECT JR, DISMUKES WE, DROMER F, et al.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America[J]. Clin Infect Dis, 2010, 50(3): 291-322.